0,beat
1,donors
2,prescribing
3,recipients
4,hretn
5,analyzed
6,case-control study
7,contributed
8,referrals
9,inflammatory
10,special access
11,findings
12,colon
13,denervation
14,retrospective
15,collinearity
16,longitudinal strain
17,metrics
18,number
19,tissue doppler
20,sensitized
21,severity
22,reversibility
23,cardiac overexpression
24,bolus
25,comorbid
26,cyclase
27,eh
28,right ventricular dysfunction
29,ventricular assist device
30,energy deficit
31,arm cuff
32,chelation
33,coupled
34,ascertained
35,diastolic mitral valve tethering
36,highly
37,sinus rhythm
38,myocyte
39,conduction
40,variance
41,lean mass
42,mean
43,61-77y
44,mr-proadm
45,care management
46,dysfunction
47,quasi-experiment
48,correlates
49,cognitive
50,multivariate analyses
51,s'lateral
52,cardioprotective effect
53,criteria
54,propensity-score
55,collaborative research
56,angina
57,concepts
58,sarcopenic range muscle
59,relationship
60,fully reversible
61,10-cell
62,triangular resection
63,inoperable
64,reoperation
65,sulfonylureas
66,saxagliptin
67,regulated
68,phosphorylation
69,left ventricular assist device
70,risk of death
71,cardiovascular events
72,catheterization
73,"n=1,203,595"
74,2-vessel cad
75,predicts
76,acetylcholinesterase inhibition
77,cost-effectiveness analyses
78,trial
79,unloads
80,resistin
81,chromatin
82,study-drug
83,tolerated
84,cohort study
85,effects
86,predictor
87,fractional shortening
88,exerts
89,unfolded protein response
90,propranolol
91,adaptive
92,thrombosis
93,nitroxyl
94,risk factor
95,science
96,adverse outcome
97,proteome
98,dyssynchronous hf
99,analyses
100,vagal tone
101,heart failure.
102,quality of life
103,atrial fibrillation
104,trials-enriching
105,frail
106,mediterranean
107,contextual
108,replicated
109,no study-related
110,peripheral muscles
111,multicenter
112,phosphocreatine
113,deficiency
114,mediated
115,intermuscular fat ratio
116,oxide donors
117,hgb
118,linear models
119,cyclic guanosine monophosphate
120,qt intervals
121,term analysis
122,regression analyses
123,elucidates
124,disorder
125,cardiac deaths
126,gene expression profile
127,occurred
128,compensatory hypertrophy
129,diabetic
130,pay-for-performance
131,pluripotency marker
132,log rank
133,training-induced
134,net economic savings
135,va
136,monocytes
137,lung
138,likelihood ratio
139,aggressive
140,hf with preserved ejection fraction
141,resource
142,vasodilator
143,bone morphogenetic protein 4
144,e'mean
145,moderate-quality evidence
146,cardiologists
147,outcomes and measures
148,new-user cohort study
149,cardiopulmonary exercise test
150,thickness
151,consultations
152,an
153,intake
154,end-stage renal disease
155,12-lead ecg
156,profiled
157,diastolic properties
158,postnatal
159,end-stage congestive heart failure
160,peripheral oedema
161,barriers
162,severe systolic hf
163,ejection time
164,kinase-2
165,renal disease
166,age-specific
167,adoption
168,nbdmards
169,diseased
170,pilot study
171,predominantly
172,nursing
173,transfer policy
174,embryonic gene
175,lyso-paf-at
176,ability
177,muscle-wasting syndrome
178,superior
179,esmolol
180,splicing
181,patent
182,indicators
183,cardiac stress
184,glucose
185,risk stratification models
186,cardiovascular society
187,authors
188,pressure ulcers
189,carvedilol
190,preserved left ventricular ejection fraction
191,purpose of review
192,genomic reprogramming
193,twofold
194,aac
195,longitudinal study
196,genotyped
197,cardiac disease
198,mutant
199,random-effects models
200,dialysis-dependent
201,allocation ratio
202,ventricular-arterial coupling
203,genes
204,diabetes mellitus
205,atrial area
206,nonfunctional channels
207,neglected
208,moderately
209,angiography
210,cardioprotective
211,computational study
212,t test
213,age-dependent
214,preoperative
215,rhythm control therapy
216,high-density lipoprotein functional
217,predictive
218,heart rate
219,interatrial shunt
220,observational study
221,cellular plasticity
222,ultrasonography
223,exertional
224,protective role
225,coprimary outcome
226,mir-25 expression
227,glycolysis
228,socioeconomic
229,generating variants
230,peak aerobic capacity
231,value=0.631
232,high-fat diet
233,complication
234,regulatory
235,end of a 10-week treatment
236,heart failure disease management
237,injections
238,reversible
239,serum cystatin c
240,pressure-volume conductance
241,stenting
242,home
243,derivation cohort
244,point of care
245,constants
246,invasively
247,transcription
248,signalling
249,systemic blood pressure
250,neurohormone
251,myxomas
252,transduction cascade
253,left ventricular systolic
254,untranslated region of messenger rna
255,pulmonary capillary wedge pressure
256,mri
257,biomedical
258,6-minute walk test
259,deacetylases
260,acetylcholinesterase inhibitor
261,paediatric
262,smoking
263,interquartile range
264,cardiovascular morbidity
265,race / ethnicity
266,apoptotic cells
267,excised
268,association
269,stent
270,functional class ranking
271,sacubiltril
272,β coefficient
273,vasopressin type 2 receptor antagonist
274,low-volume sites
275,better-than-usual support
276,gender-matched control
277,centre
278,bnp
279,medicare
280,sympathetic nervous systems
281,signaling
282,adjusted odds ratio
283,throughput
284,diastolic dysfunction
285,analyze
286,systolic dysfunction
287,citrate cycle
288,variant
289,progenitors
290,endpoints
291,neurohormonally
292,deficits
293,cardiac pathogenesis
294,sarcomeric microstructure
295,cells
296,technical
297,shunts
298,congestive heart failure phenotypes
299,r=-0.11
300,net-reclassification-improvement
301,β2-adrenergic receptor haplotype
302,value=0.027
303,antitachycardia pacing
304,reduced ef
305,schfi
306,unstable
307,chronic advanced heart failure
308,murine
309,processed
310,hazard ratio
311,electronic databases
312,re-hospitalization
313,providers
314,functional deterioration
315,area
316,therapeutic potential
317,validation
318,wall stress
319,scientific
320,malignancies
321,emergency room
322,linear mixed models
323,congestive heart failure
324,open chest model
325,haplotype
326,conjoint education
327,right ventricular fractional area
328,amenable
329,alternative
330,target
331,closure
332,overall
333,events
334,flutter
335,integral
336,shams
337,dose
338,urine
339,degree
340,noninvasive assessments
341,safety
342,heterogeneous
343,°c
344,mechanical
345,accompany
346,bound
347,low left ventricular ejection fraction
348,continuous flow
349,cardiac cachexia
350,cardiac growth
351,molecular scaffolds
352,aortic valve insufficiency
353,failure with preserved ejection fraction
354,reclassified
355,elastic
356,coordinate
357,protective effects
358,bisphophonates
359,interventricular delay
360,neoangiogenesis
361,accessibility
362,nosignificant
363,aged
364,difference
365,mammalian enabled
366,pre-post comparisons
367,novo
368,unfit
369,wave ratio
370,post
371,e / e'septal
372,diffuse
373,full potential
374,disappearance
375,panel
376,log2 ng
377,atrioventricular delay
378,all-cause
379,micrornas
380,two-vessel model
381,regulatory involvement
382,discordant
383,proteolysis
384,morphologically
385,associated
386,β-adrenergic receptor blockade
387,conserved
388,statistical standards
389,multivariable regression
390,prediction
391,medications
392,central
393,spironolactone
394,cardiovascular event
395,target audience
396,proteins
397,left ventricular dysfunction
398,2 receptors
399,progressive
400,cardiogenic shock
401,future
402,stratified
403,results
404,unanchors
405,catabolic isoenzymes
406,mistargeting
407,rs1799945
408,trastuzumab-related
409,financial incentives
410,functions
411,diseases
412,inotrope-dependent
413,maximal ventricular power index
414,trans
415,optimal treatment
416,transcriptional pause
417,mitogen-activated protein kinase
418,inotropic effect
419,transplants
420,evaluated
421,qrs complex
422,α-myosin heavy chain
423,death
424,hf-related
425,examined
426,stabilized
427,body composition study
428,in vitro
429,tailored
430,e '
431,transfusion
432,pollution
433,ventilatory efficiency slope
434,investigations
435,state
436,assessment
437,function
438,mitochondrial respiration
439,phenotypes
440,post-transplant
441,orally
442,abdominal
443,dna
444,workload
445,derivation
446,heart failure guidelines
447,demographic
448,primary end point
449,aetiologies
450,in vivo
451,chamber patterning
452,rheumatic fever
453,characterized
454,beneficiaries
455,signalling pathway
456,low-risk
457,prospective validation cohort
458,chronic disease
459,exercise-induced pasp
460,process
461,cardiac dysfunction with conduction
462,cardiovascular diseases
463,flow reserve measurements
464,systemic
465,sd
466,severely
467,acid
468,measurements
469,elucidated
470,morbidity
471,contractile reserve
472,2-vessel model
473,affect
474,perfusion
475,guideline
476,'d
477,substudy
478,cardiovascular mortality
479,ventricular action potential
480,myocardial perfusion
481,induced
482,preserved
483,autonomic dysbalance
484,ventricular tachycardia
485,systolic blood pressure
486,carotid intima-media thickness
487,eo-cfus
488,postoperatively
489,regurgitation
490,acute ischemic right heart failure
491,controlled feasibility study
492,resistance
493,antiadrenergic
494,gross national income
495,adverse events
496,registries
497,n=66
498,ventricles
499,early-onset
500,exercise-induced
501,decile
502,defined
503,incidence
504,right atrial
505,fully understood
506,acute hf 4
507,amyloidosis
508,doxorubicin-induced cardiotoxicity
509,nonterminal epitopes
510,setting
511,decline
512,aging
513,transmitral flow velocities
514,physiological
515,ejection fractions
516,decrement
517,right heart filling pressures
518,beta-blocker hypo-response
519,methylatropine
520,peritoneal dialysis
521,left ventricular systolic dysfunction
522,congenital lesions
523,end-systolic volume
524,m2
525,systolic excursion
526,options
527,osteoporosis
528,kinase
529,modulated
530,left ventricle
531,management
532,complex
533,ventricular action potentials
534,amelioration
535,inducing
536,estimated glomerular filtration rate
537,apical
538,gender-matched subjects
539,adaptation
540,tachypacing-induced hf
541,pilot
542,system
543,epigenetic readers
544,in-hospital
545,doxorubicin
546,allogeneic
547,distinguish
548,with.estimates
549,renal impairment
550,conclusions and relevance
551,mt
552,tonometric
553,radiological
554,length-force
555,coagulability
556,erythropoiesis-stimulating agent
557,cardiopulmonary bypass
558,nonpace
559,signaling paradigms
560,extracellular matrix
561,ion channelopathies
562,sustained
563,cardiopulmonary exercise testing guide
564,right heart
565,attrition
566,palliative
567,dithiothreitol
568,systematic review protocol
569,heart rate response
570,economic models
571,β2-receptor haplotype status
572,strength
573,pronounced
574,multivariate cox model analysis
575,relative
576,p38
577,cumulative hazard
578,prevention strategies
579,mirnas
580,dhand
581,reactivation
582,activated
583,exacerbation
584,risk-adjusted mortality
585,presentations
586,minimal detectable change
587,blood pressure
588,mitral filling flow
589,atrial explant-derived c-kit + cells
590,chromatin structure
591,angiotensin-converting enzyme inhibitors
592,identification
593,randomised-controlled trials
594,sphingosine-1-phosphate
595,protein drives
596,recommendations
597,major
598,techniques
599,surgeons
600,implantable cardioverter defibrillators
601,anthracycline metabolism
602,caloric restriction
603,ischemic
604,lesion
605,zebrafish
606,characteristic
607,unilateral
608,hemoglobin threshold
609,beta-blockers
610,investigation
611,participatory
612,critical
613,short-term treatment
614,exogenous
615,swine model
616,deciles
617,interval
618,pulseless ventricular fibrillation
619,attention-controlled
620,profound
621,driveline injury
622,regulation
623,systematically
624,alterations
625,apex
626,warrants
627,practice settings
628,low-quality evidence
629,explant-derived cells
630,mediator
631,matched-pairs signed-rank tests
632,glucocorticoids
633,detection
634,voltage-gated ca
635,retrospective descriptive research design
636,end of the trial
637,aortic pressure curve
638,harms
639,polytetrafluoroethylene tube
640,difference-in-differences
641,perspective
642,extract
643,asymptomatic
644,strokes
645,sheet orientation
646,renal dnx
647,nonmitochondrial protein
648,vad
649,consistent
650,tissue doppler imaging
651,risk score
652,neurohormonal systems
653,differential g-protein coupling
654,energy metabolism
655,r=-0.62
656,dash
657,programs
658,ascending
659,haematopoietic cell transplantation
660,subgroup analyses
661,cad
662,accounted
663,cardiac index
664,tm
665,mitral valve plasty
666,stabilize
667,xo
668,left ventricular filling pressure response
669,combined treatment
670,detecting
671,test
672,complications
673,right heart circulatory failure
674,oral
675,left ventricular assist devices
676,left heart twist
677,percutaneous
678,incremental shuttle walk test
679,calf muscle
680,trastuzumab-treated
681,distribution
682,eccentric
683,mitochondrial complex v activity
684,high-volume eds
685,cardioversions
686,susceptibility
687,participants
688,intensive care unit
689,parameter
690,axis function
691,cardiac event
692,left pulmonary artery
693,lack of achievement
694,direct comparison
695,raloxifene-treated
696,pathophysiological
697,serum sodium
698,regression modeling
699,liver disease
700,right atrium
701,β-blockade
702,np
703,rr
704,induce
705,occlusion
706,ivabradine-treated
707,exercise duration
708,clinically
709,shotgun
710,cardiac troponin t
711,chf-nyha-iiib
712,delivery
713,oxygen flow
714,cardiovascular outcomes
715,biopsies
716,pharmaceuticals
717,hazard ratios
718,actin cytoskeleton
719,preserved lv ejection fraction
720,pulmonary arterial systolic pressure
721,dose-dependent
722,symptom
723,social support score
724,mir-25
725,(fpassive)-sarcomere length relations
726,chart
727,man
728,hf with reduced ef
729,mass spectrometric analysis
730,alendronate
731,preferences
732,out-patient
733,oht
734,malfunctioning
735,redo sternotomy
736,guideline-recommended treatment
737,site-specific
738,hno
739,populations
740,cardiac remodelling
741,interconnected molecular pathways
742,demographics
743,skeletal muscle
744,pre-hct
745,symptomatic chronic advanced heart failure
746,setting and participants
747,independent predictor
748,intensive
749,rate constant
750,policy
751,404.x3
752,12-s
753,neprilysin inhibitor
754,practitioners
755,morphological
756,polymorphism
757,data
758,apoptotic signaling pathway
759,mena
760,grading system
761,gross income
762,onset
763,preserved ejection fraction
764,parametrized
765,blockers
766,coronary disease
767,evolution
768,haemodynamic
769,transthoracic echocardiography
770,transseptal catheterisation with transoesophageal echocardiographic
771,lying
772,central glycosylated region
773,database
774,practices
775,scores
776,restored
777,gene expressions
778,treatments
779,activate
780,dyssynchronous nonfailing
781,resynchronization
782,coronary arteries
783,cumulative
784,cardioverter-defibrillator
785,rate-control
786,social support
787,fee-for-service
788,die
789,propensity score
790,infarction-related
791,heart failure
792,circulating
793,condition
794,serum albumin
795,p=0.02
796,exposure
797,intention-to-treat principle
798,routine
799,he
800,discontinuation
801,mitochondrial structure
802,heart failure scans
803,degenerative mr
804,embolize
805,in vivo inhibition
806,parasympathetic control
807,parasympathetic function
808,6-wk
809,decreases
810,guidance
811,leg strength
812,biventricular dysfunction
813,salt loading
814,clinics
815,pulsatile devices
816,pulmonary arteries
817,hospitalization
818,renin-angiotensin system
819,theory
820,extracorporeal membrane oxygenation
821,bromodomain proteins
822,electrocardiogram
823,symptomatic systolic heart failure
824,profile
825,quality of life domains
826,qt variability
827,peripheral artery disease
828,exertion
829,relies
830,adherence
831,clinical findings
832,cardiac transplant
833,myofiber shortening
834,cytochrome c
835,univariate
836,concentrations
837,quality
838,transplant
839,cardiac filling pressures
840,pressure-overload-induced hypertrophy
841,consensus report
842,metoprolol succinate
843,noncardiologist
844,properties
845,brachial
846,renal function
847,controls
848,pre-specified analysis
849,contracting
850,carries
851,subscales
852,etiologic
853,pressure gradient
854,chronic
855,modest
856,phosphomimic
857,tolvaptan
858,foundation
859,single-arm
860,multisite studies
861,isoprenaline
862,blocked
863,nutrition
864,complementary model system
865,reduced risk
866,coronary angiography
867,kappa coefficient
868,blunts
869,interest
870,pre-participation screening
871,limitation
872,neprilysin blocks
873,controlled
874,clinical outcome
875,risk
876,autonomic nervous system
877,hazard analyses
878,natriuretic peptides
879,experienced
880,left ventricular dilatation
881,clinical outcomes
882,transcriptional analysis
883,fat mass index
884,progression
885,top pathways
886,reach statistical significance
887,mena deletion
888,proximal left anterior descending
889,p=0.036
890,cardiomyiopathy
891,downstream signalling
892,saf
893,rv
894,fixed-rate
895,extracorporeal support
896,infarction
897,ameliorates
898,procedural
899,rv failure
900,β-blocker uptitration
901,ventricular mass
902,series
903,correlations
904,beat-to-beat
905,mitochondrial dysfunction
906,markedly
907,odds ratio
908,systolic function
909,pump-exchange technique
910,dyslipidemia
911,neither
912,vegetables
913,equipotent
914,anticoagulation
915,types
916,interplay
917,characterization
918,neurohumoral blockers
919,prospectively
920,remarkable role
921,liver-specific
922,women
923,special treatment
924,ethnicity
925,precapillary pulmonary hypertension
926,breath-holding
927,antagonizing
928,health
929,frailty
930,atheromatous
931,nps
932,refractory
933,renin-angiotensin-aldosterone system
934,modulates
935,8-fluo-camp
936,functionally
937,matched
938,chronic β-adrenergic receptor stimulation
939,transient
940,occurrence
941,transgenic
942,data sources
943,modification
944,cardiomyopathies
945,crossover study
946,cost-effectiveness
947,valvular regurgitation
948,camp
949,creatinine
950,low-volume ed
951,pulmonary arterial pressure
952,reciprocal regulation
953,robust
954,halt
955,angiotensin ii
956,study
957,mrna splice variants
958,pulmonary vascular resistance
959,hydrolysis
960,catheter-based
961,nutritional strategies
962,low-volume eds
963,heart mass
964,anaerobic threshold
965,pressure volume relation
966,clinical course
967,pro-brain natriuretic peptide
968,benefit
969,current study
970,oxygen consumption
971,success rate
972,transfusion thresholds
973,adjustment
974,significant
975,statistically
976,mixed linear models
977,n=9
978,cardiac autonomic balance
979,crude
980,delayed rhythm control
981,hand
982,syndrome
983,rat
984,aspects
985,hm
986,reduced left ventricular end-diastolic pressure
987,readmissions
988,warranted
989,volume management
990,factor
991,substitution
992,full-length scn5a
993,isolated
994,responses
995,echocardiographic
996,gastrointestinal regions
997,geometry
998,systolic
999,non-hf
1000,correlation coefficient
1001,iron deficiency
1002,gene induction
1003,change scores
1004,nbdmard
1005,venous thromboembolism
1006,cardiac output
1007,identifies
1008,hazard models
1009,marked
1010,participant
1011,type 2 diabetes
1012,post-translational states
1013,evidence-based
1014,follow up
1015,mass
1016,family
1017,bhlh
1018,blockade
1019,upr
1020,fashion
1021,sst2 titrated
1022,al
1023,heart rate variation
1024,aiming
1025,severe-end-stage hf
1026,history
1027,annular ms
1028,time interval
1029,phosphocreatine resynthesis
1030,commissioning
1031,cardiac washout
1032,or
1033,antiarrhythmic drugs
1034,surrogates
1035,β-blocker-induced enhancement
1036,walking
1037,dt
1038,undiagnosed
1039,confidence intervals
1040,disease
1041,preliminary study
1042,acute coronary syndromes
1043,poses
1044,receptor
1045,outcomes
1046,circulatory derangement
1047,healthy
1048,muscle
1049,meaning
1050,methods and results
1051,human-to-human contact
1052,hospitalisation
1053,subpulmonary ventricle
1054,advocate
1055,phase
1056,practice-level variation
1057,regimen
1058,beneficial effect
1059,intravenous bolus
1060,successfully
1061,retrospective observational study
1062,homozygous
1063,biological phenotype
1064,collateral growth
1065,aortic constriction
1066,cancers
1067,oxygen uptake
1068,quality-of-life score
1069,brain natriuretic peptide
1070,right ventricular contractile function
1071,immunodetection
1072,functional capacity
1073,cardiology
1074,molecular
1075,meta-analyzed mortality
1076,volunteers--a pilot study
1077,animal
1078,hf-related cachexia
1079,rehabilitation
1080,peak ca
1081,baseline
1082,red blood cell transfusion
1083,statistical
1084,basal rotations
1085,uninephrectomy
1086,clinical
1087,met
1088,perioperative
1089,mechanism
1090,strain
1091,dialysis
1092,mechanical support devices
1093,characteristics
1094,magnetic resonance angiography
1095,icu
1096,nephrectomy
1097,ip
1098,explant-derived progenitor cells
1099,sham-dnx
1100,peak o2
1101,end-diastolic volume index
1102,her
1103,lv
1104,rabbits
1105,intubated
1106,restoration
1107,high-strength evidence
1108,statistical model
1109,end point
1110,detect
1111,signalling pathways
1112,water
1113,dilated cardiomyopathy
1114,renal
1115,aerobic exercise
1116,post-hct
1117,left ventricular assist system
1118,naturally occurring rad variant
1119,approach
1120,mitral stenosis
1121,perturbations
1122,peptides
1123,thalassaemia
1124,indication
1125,post-dash
1126,ivabradine
1127,at
1128,aldosterone antagonism
1129,i.p.
1130,consistency
1131,exercise modality
1132,bromodomain-containing protein 4
1133,stem cell source
1134,ankle-brachial index
1135,metoprolol
1136,virtual cohorts
1137,nurse
1138,electrocardiographic
1139,induced pluripotent stem cell-derived cardiomyocytes
1140,patient-years
1141,contributes
1142,os
1143,stems
1144,peripheral muscle pump
1145,renal denervation
1146,therapeutic
1147,dose-related
1148,plasma membrane translocation
1149,reduced ejection
1150,chronic hf
1151,cardiovascular death
1152,eplerenone
1153,2-way anova
1154,implantable cardioverter defibrillator-crt
1155,mitral filling flow volume
1156,embolectomy
1157,sex
1158,collagen density
1159,amino-terminal pro-b-type natriuretic peptide
1160,protein response
1161,interaction
1162,benefits
1163,donor
1164,sex-matched controls
1165,rural
1166,mechanically
1167,contextual framework
1168,infusion
1169,sex-
1170,selective beta-blockers
1171,camp production
1172,r=-0.12
1173,conducting
1174,amyloidotic pattern
1175,fatty acids
1176,prospective study
1177,presentation
1178,in vitro model
1179,homogeneous sandwich
1180,atropine
1181,conscious
1182,pediatrics
1183,adverse neurohormonal activation
1184,single-arm analysis
1185,strategies
1186,pathological
1187,trichrome blue histologic analysis
1188,negative predictive value
1189,transmitral
1190,breathing
1191,responsive
1192,sts
1193,troponin
1194,'s perspective
1195,type v
1196,pump
1197,potentially
1198,contrast agent
1199,validated
1200,technique
1201,bridge to recovery
1202,placebo-treated group
1203,diastolic tethering
1204,t1-mapping
1205,implanted
1206,urinary tract infection
1207,attributable
1208,irrespective
1209,admissions
1210,suffer
1211,matched controls
1212,favorable
1213,therapies
1214,postsystolic function
1215,post-myocardial infarction
1216,) ratio
1217,ai
1218,expression
1219,databases
1220,natural vasodilatory
1221,registry
1222,conditional
1223,madit-crt
1224,unknown
1225,systemic vascular resistance
1226,impaired
1227,co-morbidities
1228,quality indicators
1229,evidence gaps
1230,cachectic
1231,accompanied
1232,tissues
1233,systolic hf
1234,blood urea nitrogen
1235,extra corporeal membrane oxygenation
1236,industrial
1237,inverse association
1238,forty-six
1239,health care system
1240,cardiovascular function
1241,peak respiratory quotient
1242,decreased
1243,disappeared
1244,peak work rate
1245,indistinct
1246,β-myosin heavy chain
1247,multivariable analysis
1248,health care
1249,network
1250,well-treated cohort
1251,pulmonary artery snared
1252,wedge pressure
1253,operative
1254,biology
1255,drugs
1256,invasive
1257,exchange
1258,(123)i-mibg
1259,pioglitazone
1260,oxygen
1261,hemodynamic alterations
1262,individualized
1263,range
1264,briefing
1265,peak quadriceps force
1266,implantable cardioverter-defibrillator device
1267,crucial problem
1268,diagnoses
1269,left bundle branch block
1270,ischemic hf pathogenesis
1271,acute kidney injury
1272,preserved cardiac index
1273,absolute change
1274,evidence
1275,electrolytes
1276,food-frequency questionnaires
1277,test-retest
1278,left ventricle end-diastolic pressure
1279,models
1280,radial strain
1281,prescription
1282,discharge
1283,posteriorly
1284,scenario
1285,neuronal stressors
1286,re-express
1287,serum creatinine
1288,tumors
1289,precipitating factor
1290,bet
1291,cytoskeletal actin dynamics
1292,crucial
1293,postoperative
1294,perceived barriers
1295,bottleneck stenting
1296,intervention
1297,procedure-related
1298,differ
1299,population-based
1300,predictors
1301,open-label
1302,reclassification
1303,2+)-pump
1304,myocyte depolarization
1305,angiotensin receptors blockers
1306,specialty
1307,raloxifene
1308,cardiorespiratory fitness
1309,desensitizes
1310,( 2 + ) handling
1311,angiotensin-receptor neprilysin inhibitors
1312,coexist
1313,heart dilatation
1314,adjusted hr
1315,extrapolating
1316,sodium-restricted dash diet
1317,unchanged
1318,ranged
1319,exercise
1320,origin
1321,enzyme inhibitors
1322,velocity
1323,right ventricular-pulmonary arterial coupling
1324,basal
1325,steadily
1326,end-diastolic pressure
1327,sepsis
1328,antagonist
1329,autopsy
1330,extensive
1331,multivariate models
1332,acs
1333,rankings
1334,continuous-flow
1335,relaxation
1336,implantation
1337,left ventricular filling
1338,nomenclature
1339,action
1340,inhibition
1341,non-randomized
1342,radioenzymatic
1343,arginine vasopressin
1344,hf with reduced ejection fraction
1345,pulse-wave velocity
1346,lvad
1347,magnetic resonance spectroscopy
1348,capita
1349,additive effect
1350,diminished
1351,hypertrophied heart
1352,sympathetic
1353,sham-operated
1354,reduce
1355,neurohormones
1356,benign
1357,antihypertensive medication
1358,research
1359,descriptive study
1360,prevention
1361,ees
1362,humans
1363,awful paradox
1364,scar
1365,cutoff
1366,liver texture
1367,rv support
1368,stretch rate
1369,p=0·016
1370,parallel-group
1371,cardiac filling
1372,roles
1373,control
1374,natremia
1375,drug-free
1376,interfere
1377,simulated
1378,nontrastuzumab
1379,serious harms
1380,anticoagulants
1381,hemocompatibility
1382,in
1383,standard practice
1384,right
1385,chronic kidney disease
1386,qt interval
1387,serum
1388,end-systole
1389,device
1390,prespecified criteria
1391,p=0·0001
1392,sudden
1393,63c→g
1394,genetic
1395,3-vessel cad
1396,factors
1397,rates
1398,rate reduction
1399,energy expenditure
1400,bisoprolol
1401,assay
1402,repolarization
1403,stemming
1404,exacerbates
1405,severe
1406,occluded
1407,growth factor beta-dependent yield
1408,implicated
1409,instability
1410,secondary end points
1411,no
1412,coronary artery occlusion
1413,qualitative study
1414,myocardial infarction
1415,echocardiography
1416,10-eo-cfu
1417,abnormalities
1418,chronic myocardial ischemia
1419,protein kinase
1420,positron emission tomography
1421,defibrillator-only
1422,followed up
1423,pulmonary arterial systolic pressure relationship
1424,exercise oscillatory ventilation
1425,heart failure with preserved
1426,acute care
1427,central blood pressure
1428,life
1429,periodic breathing
1430,treatment
1431,ventricular diastolic function
1432,carcinoma
1433,led
1434,hfpsi
1435,midregional proanp
1436,circumferential strain
1437,doses
1438,robot-assisted
1439,aortic valve surgery
1440,enriched
1441,fat distribution
1442,serial
1443,segment
1444,ischemic mitral regurgitation
1445,cardiovascular reserve
1446,bioprosthetic valve replacement
1447,hemoglobin
1448,vasodilators
1449,modeled
1450,adenine nucleotides
1451,hdl
1452,calcineurin
1453,neutral
1454,procedures
1455,nondiabetic
1456,hypothesize
1457,single-centre
1458,immunoreactive
1459,quality improvement
1460,universal definition
1461,exhaustion
1462,erc
1463,chronic organ failure
1464,fatigue
1465,preventive
1466,care
1467,phosphorylation sites
1468,interleukin receptor family member
1469,current
1470,tissue
1471,under general anaesthesia
1472,stroke
1473,gender
1474,pg
1475,common consensus
1476,imaging techniques
1477,treatment strategies
1478,myofibrillar
1479,emergency department
1480,pulmonary hypertension
1481,infrequent
1482,subdomains
1483,surgery
1484,differential relations
1485,malfunctions
1486,formed
1487,embolism
1488,blood flow
1489,practice-level differences
1490,relative reduction
1491,kidney infection
1492,doctors
1493,eccentric hypertrophy
1494,chronic acf
1495,background
1496,processes
1497,time-domain
1498,physicians
1499,decrease
1500,left ventricular diastolic function
1501,heart failure mortality
1502,biomarkers
1503,pacing
1504,indices
1505,accountable
1506,adenoviral vector
1507,hypothesis
1508,sst2
1509,practitioner
1510,right ventricle
1511,depressed left ventricular
1512,all-cause readmission
1513,levels of social support
1514,expressing
1515,systole
1516,nuclear factor
1517,retrospective cohort
1518,cell death
1519,6-min walk test
1520,pace
1521,prognostic
1522,β-ar responsiveness
1523,pre-pd
1524,p=0.004
1525,cardioprotection
1526,inhospital
1527,non-diabetic
1528,mitral valve area
1529,exercise + diet
1530,proximal
1531,exercise testing
1532,actin cytoskeleton pathways
1533,interpretation
1534,isoproterenol
1535,uncommon
1536,thrombotic obstruction
1537,pulmonary embolism
1538,end-of-life treatment
1539,infancy
1540,trastuzumb-related chf
1541,snared
1542,method
1543,severe systolic heart failure
1544,hemodynamics
1545,obesity
1546,randomized
1547,resolution
1548,stiffness
1549,highly expressed
1550,4-fold
1551,well-being
1552,wild-type
1553,retrospective chart review
1554,measure
1555,protocol-driven poc testing
1556,acute coronary syndrome
1557,nonsurvivors
1558,post-pd
1559,exercise performance
1560,cachexia
1561,venoarterial dilation
1562,bottleneck shape
1563,cases
1564,initiation
1565,hf-action
1566,circulatory support
1567,physiologic
1568,ec
1569,central pattern generator
1570,mitochondrial ultrastructural changes
1571,treated
1572,steady
1573,pairwise comparisons
1574,weight
1575,catabolism
1576,systematic review
1577,urine volume
1578,mass index
1579,body mass
1580,sensitive
1581,albumin
1582,ischemic cardiomyopathy
1583,protective
1584,alleviate
1585,myocardial diastolic dysfunction
1586,determinant
1587,evaluation
1588,differential analysis
1589,atrium
1590,acute myocardial infarction
1591,microarray
1592,beta blockers
1593,debilitating
1594,angiotensin receptor blockers
1595,mitral valve
1596,telephone support
1597,right ventricular assist device
1598,destabilized
1599,blot
1600,hearts
1601,consumption rate
1602,coronary artery calcium scores
1603,invasive haemodynamic assessment
1604,deaths
1605,trend
1606,quantitative analysis
1607,n=197
1608,protein
1609,interaction=0.032
1610,confirmatory factor analysis
1611,(-)-erc
1612,septal
1613,cycle
1614,medication
1615,emotional stress
1616,epigenetic
1617,cell
1618,rhythm
1619,reference
1620,severe heart failure
1621,assist device
1622,anabolic
1623,1.5-t
1624,taxonomy
1625,leading
1626,angiotensin-receptor blockers
1627,interatrial shunting
1628,n=100
1629,safety monitoring board
1630,families
1631,overexpress
1632,resistant
1633,kappa coefficients
1634,esrd
1635,life-threatening
1636,wall thickness
1637,experimental
1638,cpg
1639,dimensions
1640,adverse outcomes
1641,eseptal
1642,chronic insulin exposure
1643,structure
1644,jehovah 's witness
1645,left-hand
1646,economic considerations
1647,randomize
1648,knockdown
1649,dual-energy x-ray absorptiometry
1650,pb
1651,inotropes
1652,variability
1653,patients
1654,filling pressure
1655,fit
1656,guideline-recommended target dose
1657,single-institution cohort
1658,post-translational
1659,molecular analysis
1660,angioplasty
1661,veterans
1662,aortic valve
1663,camp hydrolytic activity
1664,assisted
1665,protocols
1666,diastolic function
1667,growth
1668,artery disease
1669,applied
1670,cardiologist
1671,nucleolin
1672,interview
1673,relieve
1674,depressive
1675,contributions
1676,treadmill exercise testing
1677,maladaptive
1678,valvular
1679,subspecialty
1680,chromatin subproteome
1681,emd
1682,cardiopulmonary exercise testing
1683,correlated
1684,post-aac
1685,pulmonary congestion
1686,apoptosis
1687,absence
1688,noninvasive
1689,myocytes
1690,outpatient
1691,phospholamban
1692,significantly
1693,case-control analysis
1694,correction
1695,co
1696,atherosclerosis
1697,mitochondrial-targeted peptides
1698,right-sided cardiac catheterization
1699,response
1700,quintile
1701,variables
1702,brachial systolic pressure
1703,standard error of measurement
1704,young
1705,trpm7
1706,reversed
1707,pathophysiologically
1708,systolic mitral annulus velocity
1709,efficacy
1710,lusitropic
1711,nicorandil
1712,right ventricular end-diastolic area index
1713,dietary sodium restriction
1714,study-a multicenter
1715,sympathovagal balance
1716,low left ventricular ejection fractions
1717,catecholamine
1718,anthracycline-induced cardiotoxicity
1719,.97s
1720,uti
1721,coronary interventions
1722,support
1723,phenotype
1724,circulatory assist device
1725,right atrial pressure
1726,valve plasty
1727,eligibility status
1728,quality of life score
1729,arterial tonometry study
1730,mrna
1731,cardiovascular event rate
1732,potential
1733,sample
1734,arterial pressure
1735,right ventricular pump function
1736,survival
1737,periprocedural
1738,prodrug
1739,lateral wall
1740,effects analysis
1741,causes
1742,(drs)-stratified analyses
1743,human
1744,proangiogenic effects
1745,additive
1746,simulation
1747,left-to-right
1748,recurrent
1749,hypotension
1750,pef
1751,rationale
1752,shunt
1753,uptake
1754,people
1755,inferior vena cava
1756,signal transduction
1757,404.x1
1758,elevated
1759,emotional
1760,regulator
1761,writer
1762,heart-specific
1763,2+)-stimulated atpase activity
1764,outcome
1765,quality-of-life
1766,rnas
1767,standard
1768,ostensibly
1769,exercise training
1770,chf
1771,parasympathetic tone
1772,left ventricular
1773,dyssynchronous heart failure
1774,resection
1775,cardiac angiogenesis
1776,interactions
1777,persist
1778,endothelial dysfunction
1779,etiologies
1780,external
1781,composite end-point
1782,pacemakers
1783,arterial tonometry
1784,eligible
1785,magnetic resonance imaging
1786,cardiac explant
1787,nurses
1788,cost-effective
1789,ami
1790,( hdl )
1791,β2-receptor
1792,left anterior descending artery
1793,left ventricular function assessment
1794,collagen
1795,nuts
1796,national
1797,attenuated
1798,office
1799,line
1800,lower event rate
1801,prospective studies
1802,sci
1803,gadolinium-chelate contrast agent
1804,ischemic conditioning
1805,moderate-intensity
1806,effect
1807,hazards
1808,diastolic failure
1809,postcontrast
1810,cardiac magnetic resonance postcontrast
1811,angiotensin-converting enzyme inhibitor
1812,calcium-sensitizing agents
1813,right atrium mass
1814,bradyarrhythmias
1815,nontreatment
1816,severe end-stage hf
1817,hyperinsulinemia
1818,single-payer perspective
1819,joint effect
1820,transplantation
1821,vagal
1822,prescriptive 4-year survival
1823,muscles
1824,evoked
1825,nitrite
1826,efficiency
1827,differential effect
1828,heart transplant
1829,ablation
1830,hypothetical
1831,guideline-recommended drugs
1832,fm
1833,antagonists
1834,differentially
1835,functional status
1836,denotes
1837,pharmacologic
1838,protocol
1839,independently
1840,bundle-branch block
1841,transfusions
1842,spectrometry
1843,end of life
1844,electrical activation
1845,chronic hf-ref
1846,protein 's efficacy
1847,monoclonal antibodies
1848,facilities
1849,period
1850,cardiovascular system
1851,sequence
1852,major predictor
1853,titin
1854,model
1855,end-systolic elastance
1856,serum factors
1857,level of agreement
1858,post-tac
1859,myocardial angiogenesis
1860,prevalence
1861,emean
1862,post-acute
1863,changes
1864,free wall
1865,end stage
1866,ventricular cardiomyocytes
1867,implantations
1868,ras
1869,ratings
1870,chromatin subproteomes
1871,life-sustaining treatment
1872,high-density lipoprotein
1873,anemia
1874,ischemic cause
1875,flow
1876,beta1-adrenergic receptor
1877,systematic
1878,pathological stress
1879,pulmonary arterial hypertension
1880,preserved left ventricular
1881,insignificant ms
1882,prolongation
1883,inotropic
1884,systolic dysfunction treatment
1885,cardiotoxicity
1886,signs
1887,serum potassium
1888,mmol
1889,rotation
1890,functional class ii
1891,consequences
1892,fully magnetically levitated lvas
1893,risk factors
1894,blots
1895,operationalized
1896,comanagement
1897,hypertrophy
1898,cardiac failure
1899,cardiac catheterization
1900,sensitivity
1901,linear pathway
1902,insertion
1903,channel-dependent
1904,computing
1905,vascular
1906,periodic
1907,double-knockout
1908,heterochromatic chromatin
1909,width
1910,ejection fraction
1911,successful
1912,caspase-3
1913,noncardiac
1914,switched
1915,fat mass
1916,cohort analysis
1917,endothelial-protective effects
1918,dietary
1919,cultured cardiomyocytes
1920,beta blockade
1921,cost of the intervention
1922,mediate
1923,inflammation
1924,selectively
1925,characteristic curve
1926,fluid overload
1927,independent hypotheses
1928,identified
1929,inducible
1930,weak grip
1931,autologous
1932,hf-ref
1933,university
1934,male
1935,continuous relationship
1936,nodularity
1937,biosynthetic enzymes
1938,rehospitalization
1939,severe developmental impairment
1940,creatine kinase activity
1941,astronaut
1942,edge detection
1943,non-linear hr variability measures
1944,solid
1945,echocardiograms
1946,electrical activation sequence
1947,endothelial no synthase activation
1948,power
1949,right ventricular pacing
1950,device-related
1951,affected
1952,risk stratification
1953,differentiation
1954,incubated
1955,vs
1956,composite endpoint
1957,clinical practice guidelines
1958,enrollment
1959,multicenter study
1960,filling pressures
1961,effector molecules
1962,xo-mediated ros
1963,odds ratios
1964,clustering
1965,left ventricular ejection fraction
1966,coronary artery disease
1967,ischemic events
1968,toxicity
1969,two-center
1970,risk prediction
1971,dobutamine
1972,immunoassays
1973,anti-oxidant defence
1974,x-ray absorptiometry
1975,subproteome
1976,regeneration
1977,systolic elastance
1978,cause
1979,resistive
1980,biologic
1981,age-matched
1982,pressure-overload hypertrophy
1983,sex-specific model
1984,irs1
1985,plasticity
1986,chronic heart failure
1987,heart iron
1988,historical
1989,receptor blockers
1990,admission
1991,explored
1992,glucose oxidation
1993,gut
1994,low-dose
1995,myxoma
1996,stenotic physiology
1997,cardiac energy metabolism gene expression
1998,compliance
1999,contractility
2000,sphingosine-1-phosphate receptor 1
2001,hipsc-cms
2002,development
2003,reduction
2004,downregulated
2005,ch
2006,antiarrhythmic medication
2007,pathobiology
2008,myocardial ischaemia
2009,catalytic
2010,load-corrected chronotropic response
2011,left bundle branch block pattern
2012,attenuation
2013,nonspecific
2014,cross-sectional
2015,quality measures
2016,anthracycline-containing chemotherapy
2017,therapeutics
2018,failure
2019,starting
2020,design
2021,α=0.96
2022,hypothermic circulatory arrest
2023,projections
2024,perspectives
2025,mets
2026,sodium-restricted
2027,parasympathetic neurotransmission
2028,influences
2029,randomised
2030,testosterone
2031,3m
2032,uncertainty
2033,confidence
2034,concentration
2035,cellular
2036,assessed
2037,enrolled
2038,cardiac plasma membrane levels
2039,inhibitors
2040,normal filling pressures
2041,downregulation
2042,lean body mass
2043,ring
2044,p=0.03
2045,arterial compliance
2046,age groups
2047,test-retest reliability
2048,non-ischemic
2049,histological analysis
2050,second-generation sulfonylureas
2051,implantable cardioverter-defibrillator
2052,stress echocardiography
2053,non-dilated left ventricle
2054,effectiveness
2055,if-channel inhibition
2056,st2
2057,office-based
2058,congenital heart lesions
2059,residual confounding
2060,infection
2061,trends
2062,cardiac transplants
2063,overweight
2064,ventricular wall stress
2065,scales
2066,targets
2067,health-care
2068,post-lvad
2069,placebo-treated
2070,transmitral flow
2071,perceived
2072,thromboembolic events
2073,positive
2074,congestive hf
2075,consecutive
2076,time-dependent
2077,left ventricular longitudinal systolic strain
2078,proof-of-principle cohort study
2079,nutritional
2080,identify
2081,dyspnea
2082,gene expression
2083,glucocorticoid
2084,endothelial function
2085,macrophages
2086,stress
2087,binomial regression models
2088,credible interval
2089,noncardiovascular
2090,pacemaker
2091,nonselective
2092,society
2093,angiotensin-receptor blocker
2094,measures
2095,end points
2096,serious
2097,accessory pathways
2098,categorization
2099,contribution
2100,hemostasis
2101,β-ar
2102,volume
2103,crf
2104,curve
2105,obese
2106,clinical practice
2107,animals
2108,physician
2109,inability
2110,study design
2111,decoy
2112,lipoprotein-associated phospholipase a2
2113,progenitor cells
2114,internal
2115,molecular biomarkers
2116,transforming growth factor-β
2117,detrimental alterations
2118,coupling
2119,explanted
2120,tachyarrhythmias
2121,beta-adrenergic
2122,coronary heart disease
2123,norepinephrine
2124,considerable
2125,diastolic murmurs
2126,migration
2127,central venous pressure
2128,risk predictor
2129,speckle tracking echocardiography
2130,lvet
2131,arrhythmia
2132,diastolic mitral annular velocity
2133,endpoint
2134,stimulated
2135,disposition
2136,wild-type rad
2137,anthracycline-related congestive heart failure
2138,center
2139,end-stage heart failure
2140,lesions
2141,tachycardic
2142,comorbidities
2143,immunoprecipitation
2144,administration
2145,beats
2146,cardiac injury
2147,psss
2148,57-year-old man
2149,tug test
2150,normalized
2151,life-threatening situation
2152,conditions
2153,surgical
2154,ranked
2155,procedure
2156,recovery
2157,stent occlusion
2158,ml
2159,survivors
2160,mrnas
2161,sarcomere
2162,quartile
2163,mechanical cardiac support
2164,cost analysis
2165,act
2166,paced
2167,fluctuations
2168,reduced wall stiffness
2169,cholesterol
2170,averted
2171,renal dysfunction
2172,competitive
2173,sham
2174,cessation
2175,acute pulmonary embolism
2176,systematic monitoring
2177,vascular stiffness
2178,cardioprotective signaling
2179,angiotensin receptor neprilysin inhibitor
2180,phenylephrine
2181,acute autonomic nervous system modulation
2182,diastolic filling formalism
2183,rvpo
2184,mitochondrial-targeted antioxidant
2185,end-diastolic volume
2186,counterparts
2187,β1ar
2188,quality of care
2189,patterns
2190,autonomic imbalance
2191,length of stay
2192,score range
2193,renin inhibitors
2194,mitochondrial oxidative stress induced
2195,cytotoxic
2196,arrhythmias
2197,acute anthracycline-induced cardiotoxicity
2198,subcellular alterations
2199,acp
2200,multisite study
2201,exercise-induced pulmonary artery systolic pressure
2202,hf
2203,flow-mediated dilatation
2204,cardiac remodeling
2205,2-fold
2206,stimulation
2207,ros
2208,transcript
2209,complementary
2210,differential impact
2211,mitral annulus velocities
2212,annular size reduction
2213,rate
2214,icd
2215,mice
2216,renal artery stenosis
2217,biomarker
2218,sympathetic control
2219,length-force relationship
2220,net reclassification improvement
2221,antagomir
2222,disease progression
2223,prediction rule
2224,declines
2225,ameliorated
2226,intestinal
2227,postmarketing
2228,medicine
2229,cross talk
2230,tend
2231,acute right ventricular pressure overload
2232,breathlessness
2233,primary outcome
2234,vs.
2235,not
2236,electron microscopy
2237,community-based cohort
2238,endopeptidase inhibitors
2239,rv dysfunction
2240,hf-action cohort
2241,transcription factors
2242,β-blocker uptitrations
2243,cell senescence
2244,non-lbbb
2245,inpatient
2246,chronically
2247,proportional hazards models
2248,right heart failure
2249,tone
2250,angiotensin-aldosterone pathway
2251,elateral
2252,endothelin
2253,angiogenesis
2254,amplitude
2255,molecular dysfunction
2256,caspase 3
2257,end-systolic pressure
2258,catabolic
2259,compensated hfpef
2260,gg
2261,gastrointestinal bleeding
2262,diagnostic
2263,adenosine
2264,end-tidal co2
2265,surrogate
2266,clin
2267,ng
2268,copd
2269,abrogate
2270,beginning
2271,fundamental definitions
2272,ventricular assist device support
2273,avp
2274,cardiac apoptosis
2275,proximal lad
2276,cost-effectiveness ratios
2277,acute rv failure
2278,parasympathetic activity
2279,signaling pathway
2280,multivariable adjustment
2281,defined prediction rule
2282,surgically
2283,choline
2284,susceptible
2285,caloric
2286,evaluable plasma samples
2287,confounders
2288,drug treatment
2289,modulation
2290,followed
2291,risk-standardized
2292,right pulmonary artery
2293,mitochondrial oxidative phosphorylation capacity
2294,evolving
2295,weak recommendation
2296,nmol
2297,left ventricular filling pressure
2298,cardiac death
2299,acetyltransferases
2300,population
2301,technology
2302,body mass index
2303,capability
2304,long-term support
2305,risk model
2306,absorption
2307,early-outgrowth colony-forming units
2308,crt
2309,hemodynamic status
2310,follow-up
2311,heartmate
2312,high-frequency
2313,walk test distance
2314,rate-control strategies
2315,diuretics
2316,data analysis
2317,age
2318,β-adrenoceptor blockade
2319,hyperkalemia
2320,preserved mitral valve opening
2321,max
2322,paradigm-hf
2323,relative risk
2324,aor
2325,exacerbated
2326,frame
2327,electromechanical
2328,quality of life assessment
2329,abundance
2330,epidemic
2331,ans
2332,meq
2333,rat left ventricular
2334,blood pressure control
2335,washout
2336,edge-to-edge anastomosis
2337,advanced
2338,quality-adjusted survival
2339,dopamine
2340,unfavorable outcome
2341,canine model
2342,wk
2343,cardiomyopathy
2344,interventions
2345,gene
2346,p=0.022
2347,requirement
2348,under the curve
2349,lability
2350,diastolic mitral flow velocity
2351,randomized study
2352,plasma norepinephrine
2353,influence
2354,multiparametric
2355,variants
2356,followed-up
2357,transcription factor networks
2358,potassium
2359,dxa
2360,epinephrine
2361,fat
2362,mechanics
2363,kinases
2364,diagnosed
2365,synthesise
2366,high-dose
2367,anxiety
2368,breakdown
2369,institution
2370,metabolic exercise
2371,currents
2372,deactivation
2373,pathway
2374,decreased left ventricular ejection fraction
2375,initial results
2376,namely
2377,associations
2378,collateral growth patterns
2379,pediatric
2380,symptomatic
2381,diabetes
2382,cost-minimization approach
2383,performance measurement systems
2384,prognostically
2385,mva
2386,health-related
2387,frequency
2388,binding
2389,laboratory
2390,ratio
2391,medical
2392,contractile response
2393,transient receptor potential cation channel
2394,advanced management
2395,event-free
2396,lf
2397,placebo
2398,high-risk subgroups
2399,tomographic angiography
2400,lad
2401,hospitalisations
2402,died
2403,biomedical treatment
2404,strain rate
2405,ranging
2406,plasma catecholamines
2407,fetal gene
2408,strong
2409,aimed
2410,particles
2411,pressure development
2412,peripheral edema
2413,cardiopulmonary resuscitation
2414,renal underperfusion
2415,medical history
2416,fat-free mass index
2417,communicate
2418,composition
2419,derived
2420,antecedent
2421,longitudinal change
2422,allopurinol
2423,interrelated
2424,retrospective studies
2425,induction
2426,nordic walking
2427,truncated fragments
2428,disease-specific
2429,renal failure
2430,endothelial cell
2431,postcontrast t1 time
2432,receptor antagonists
2433,ambulatory
2434,stable
2435,functional assessment
2436,current treatment
2437,improvement
2438,albeit
2439,tolerance
2440,skilled
2441,systolic heart failure
2442,diastolic
2443,dd
2444,prospective
2445,downstream
2446,c-kit + cells
2447,molecule
2448,aortic
2449,storm
2450,deranged ca
2451,p38α
2452,pump replacement
2453,biomarker-guided
2454,web
2455,testosterone supplementation
2456,stimuli
2457,multivariate regression
2458,guideline-recommended
2459,institutions
2460,exchanges
2461,all-cause hospitalisations
2462,adverse event
2463,exercise capacity
2464,peripheral vascular disease
2465,renin-angiotensin-aldosterone system inhibitors
2466,empirically
2467,blood testing
2468,develops
2469,nonstandardized
2470,prognosis
2471,refill
2472,blood-flow paths
2473,non-aa
2474,responsiveness
2475,post-lvad ai
2476,detected
2477,cardiac
2478,diastolic mitral leaflet motions
2479,problems
2480,children
2481,antiplatelet medication
2482,diagnosis
2483,drug-untreated
2484,congestion-like
2485,primary
2486,insulin receptor substrates 1
2487,treating
2488,consistently
2489,contractile efficiency
2490,faster turnaround
2491,molecular pathways
2492,strategy
2493,oxidative stress markers
2494,rigorous investigation
2495,neuro-hormonal system
2496,right ventricular support
2497,discharged
2498,vascular endothelial growth factor
2499,high-risk
2500,cardiac dysfunction
2501,comorbidity
2502,clinicians
2503,osteomedullary biopsy
2504,aldosterone antagonist
2505,baseline glomerular filtration rate
2506,dynamic
2507,elderly
2508,pf
2509,anesthetized
2510,nuclear factor-κb
2511,plasma
2512,fragmentation
2513,platelet-activating factor
2514,recruitment
2515,dementia
2516,non-linear
2517,spontaneous
2518,univariable analysis
2519,adipose tissue
2520,counterbalance
2521,polymerase ii
2522,male wistar
2523,correlate
2524,east
2525,implementation strategies
2526,conservation
2527,awareness
2528,correlation
2529,applicable
2530,iron homeostasis
2531,acute hf
2532,gls
2533,nct00180271
2534,overstimulation
2535,attention
2536,mitochondrial
2537,postmenopausal women
2538,up-regulated
2539,status
2540,proteomics
2541,sympathetic tone
2542,descriptive statistics
2543,dilatation
2544,concentric left ventricular hypertrophy
2545,first-in-class inhibitor
2546,prevalent
2547,investigated
2548,hemodynamic
2549,odds
2550,phosphodiesterase-2
2551,waves
2552,bb
2553,chf-dnx
2554,cardiac rehabilitation
2555,aha
2556,array
2557,peripheral arterial disease
2558,data point
2559,cross-linking
2560,differentially expressed genes
2561,adiponectin
2562,stroke volume index
2563,regression analysis
2564,mild
2565,unloading
2566,contractile function
2567,acute treatment
2568,internists
2569,terminologies
2570,myocardial t1
2571,cardiomyocyte-like cells
2572,protected
2573,sympathetic outflow
2574,agonist
2575,high-cost
2576,all-cause readmissions
2577,insurance
2578,revascularization
2579,signalling cascades
2580,volume overload
2581,deterioration
2582,degenerative mitral regurgitation
2583,nationwide
2584,mitochondrial oxidative metabolism
2585,acetyltransferase
2586,lifesaving drugs
2587,component
2588,herbal medicine
2589,visit
2590,conclusion and relevance
2591,t2 *
2592,micronutrients
2593,refractory right heart failure
2594,descriptive assessment
2595,early-activated septum
2596,actrn12610001087044
2597,opening
2598,oxidase
2599,germline
2600,tool
2601,hallmark
2602,protective effects of exercise training
2603,diet
2604,propensity score-matched analyses
2605,all-cause mortality
2606,α-subunit
2607,discrepancy
2608,leaflet
2609,functional
2610,composite end point
2611,enzymes
2612,post hoc analysis
2613,diastolic stiffness
2614,left ventricular tissue
2615,transcatheter
2616,limbs
2617,trastuzumab
2618,safety end point
2619,25mg
2620,acting
2621,lactate
2622,guide
2623,treadmill testing
2624,renin-angiotensin system blocker
2625,case
2626,negative
2627,epifluorescence microscopy
2628,self-rated depression scores
2629,reduced capillary
2630,precapillary
2631,magnetically levitated rotor
2632,engage
2633,athletes
2634,admitted
2635,be
2636,composite quality measure
2637,cyclic
2638,publications
2639,markers
2640,malignant
2641,rise
2642,augmented
2643,sonographic
2644,therapy
2645,knowledge
2646,inactive
2647,effective
2648,diastolic blood pressure
2649,consecutive case
2650,variable
2651,psychometric testing
2652,transverse aortic constriction
2653,longitudinal performance
2654,observational cohort studies
2655,irs2
2656,calreticulin
2657,energy substrate metabolism
2658,secondary outcome
2659,pathogenesis
2660,delineated
2661,exercise time
2662,targeting
2663,consensus
2664,immunohistochemistry
2665,heart transplantation
2666,hypoxia
2667,right heart circulation
2668,values
2669,β-blockers
2670,telehealth
2671,β-ar drive
2672,median
2673,shocks
2674,incident
2675,testing
2676,cardiac transplantation
2677,adjunctive treatment
2678,hand-searching
2679,ring annuloplasty
2680,decompensation
2681,dramatic
2682,gluconeogenesis
2683,mlhf
2684,satisfaction
2685,prolonged emd
2686,cardiac risk
2687,performers
2688,risk avoidance
2689,sitagliptin
2690,swine
2691,infarct
2692,academic
2693,p=0·0004
2694,higher-than-expected rates
2695,enos-thr
2696,posterior wall
2697,developed
2698,monitor
2699,activity
2700,left ventricular diastolic end diameter
2701,accounting
2702,assembly
2703,abstract
2704,ckd
2705,examination
2706,neonatal rat
2707,recruited
2708,insight
2709,likelihood
2710,euthanization
2711,(-)-epicatechin-rich cocoa
2712,2-year study
2713,sympathetic activity
2714,risk reduction
2715,polymorphisms
2716,congestive
2717,essential
2718,well
2719,neprilysin inhibition
2720,transcription factor
2721,brd4
2722,within-day test-retest
2723,community-based
2724,indications
2725,translational repression
2726,smoked
2727,dyssynchrony
2728,communication
2729,research design
2730,intravenous inotropes
2731,cost-effectiveness limits
2732,functional class
2733,intraclass correlation coefficient
2734,rs10927887
2735,classified
2736,duplicate
2737,mo
2738,tools
2739,tumor necrosis factor
2740,clinician
2741,networks
2742,echo-doppler cardiography
2743,symptoms
2744,user
2745,p70s6k
2746,program
2747,anthracycline
2748,pro-adrenomedullin
2749,white
2750,chronic systolic heart failure
2751,ethnic
2752,readmission
2753,safe
2754,elicited
2755,mapped
2756,reliable
2757,features
2758,epicatechin-rich cocoa
2759,concern
2760,continuous wave doppler echocardiography
2761,continuity equation
2762,midpapillary
2763,low-volume
2764,right ventricular
2765,deficit index
2766,centrifugal flow pump
2767,control model
2768,aortocaval fistula
2769,channel
2770,cardiovascular
2771,linked
2772,lvas
2773,covariates
2774,implant
2775,strata
2776,left ventricular biopsies
2777,study selection
2778,egfr
2779,carbohydrates
2780,fibrosis
2781,physical
2782,longitudinal outcome-monitoring
2783,atropine infusion
2784,projecting
2785,modestly
2786,implants
2787,operations
2788,reduces
2789,stroke volume
2790,subvalvular
2791,operation
2792,nonprescribing
2793,mapping
2794,individuals
2795,ultrastructural
2796,risks
2797,insulin-signaling
2798,walked distance
2799,mineralocorticoid receptor antagonists
2800,first-in-man experience
2801,atrial
2802,adults
2803,remodeling
2804,iron-deficient
2805,heart pathology
2806,hdl-induced no production
2807,metabolic pathways
2808,defects
2809,energy
2810,6mwt
2811,waist circumference
2812,heart
2813,depression
2814,cardiac events
2815,proteomic remodeling
2816,inhibitory
2817,psoriasis
2818,interruption
2819,differential response
2820,c statistics
2821,heterogeneity
2822,replacement
2823,oxide
2824,respiratory gas analysis
2825,sarcoplasmic reticular
2826,curative
2827,hospitalized
2828,advanced stages
2829,prognostic factor
2830,endothelial
2831,pathways
2832,insulin resistance
2833,twist
2834,blot analysis
2835,ventricular assist devices
2836,non-biological disease modifying antirheumatic drug
2837,left anterior descending
2838,inverse correlation
2839,dearth
2840,side
2841,blood
2842,clinic
2843,altered
2844,unclear
2845,transiently
2846,reduced left ventricular ejection fraction
2847,driveline
2848,underlie
2849,diuretic resistant volume overload
2850,single-cohort study
2851,aortic valve replacement
2852,rs8187710
2853,cornerstone
2854,coronary artery ligation
2855,sport
2856,fiber
2857,cardiac hypertrophy
2858,components
2859,trials
2860,general population
2861,factorial
2862,integrated discrimination improvement
2863,pigs
2864,acute dyspnea
2865,mitral valve opening
2866,myocyte diameter
2867,validity
2868,resolved
2869,depresses
2870,detergent
2871,pulmonary
2872,multivariate assessment
2873,measurement
2874,functional classification
2875,significance
2876,hemolysis
2877,salt
2878,noncoding
2879,self-management
2880,cohort
2881,primary endpoint
2882,mortality
2883,mouse
2884,hypoalbuminemia
2885,guidelines
2886,phenylephrine-induced genes
2887,soluble
2888,rheumatoid arthritis
2889,developmental chromatin remodeling events
2890,mixed-methods study
2891,ste
2892,force
2893,lead
2894,end stage kidney failure
2895,metabolism
2896,patient-level regression
2897,ecgs
2898,dilated
2899,maintenance
2900,heart rate reduction
2901,excitation-contraction
2902,serum resistin
2903,integrate
2904,replicating
2905,armamentarium
2906,restorative
2907,resource utilization
2908,recent findings
2909,neurological
2910,lcx
2911,mitochondrial energy production
2912,fewer st-segment-elevation mis
2913,hypertrophic
2914,scarce
2915,sham-inv
2916,nephropathy
2917,hfvt(+)
2918,basal contractility
2919,septum
2920,cm2
2921,uptitrations
2922,right coronary artery
2923,adipokines
2924,risk-adjusted
2925,mitral regurgitation
2926,antibodies
2927,spite
2928,6-minute walking distance
2929,radial artery tonometry
2930,systolic ventricular function
2931,intravenously
2932,causal
2933,readers
2934,goal
2935,heart failure-related
2936,angiotensin converting enzyme inhibitor
2937,erasers
2938,hospital
2939,wild type
2940,equitable
2941,ctnt
2942,cardiac magnetic resonance imaging
2943,aric
2944,ventricularly paced
2945,statistic
2946,leukocytes
2947,ms
2948,noted
2949,dl
2950,functional class iii
2951,altering
2952,cgmp synthesis
2953,titrated
2954,pulmonary arterial vasculature
2955,r=0.67
2956,air
2957,inconsistent results
2958,characterize
2959,lean
2960,failure with reduced ejection fraction
2961,renin-angiotensin-aldosteron
2962,ref
2963,quantified
2964,feeding
2965,protein expression
2966,wall
2967,exploratory factor analysis
2968,myocardial tissues
2969,double-blind
2970,mitochondrial function
2971,aldosterone blockade
2972,exercise rehabilitation
2973,ventricular structure
2974,implications
2975,infusions
2976,abolished
2977,insulin
2978,randomly
2979,etidronate
2980,bridge to transplantation
2981,high-quality work
2982,variation
2983,lc-ms
2984,population-specific
2985,adverse
2986,oxidase inhibition
2987,cancer
2988,outpatients
2989,up
2990,caused
2991,impact
2992,breathing control
2993,pulsatile afterload
2994,fluid retention
2995,post-translational state
2996,performance
2997,mg
2998,normal
2999,diastolic filling time
3000,enhanced
3001,left ventricular ejection time
3002,concurrent
3003,ste analysis
3004,objectives
3005,affects
3006,conclusion
3007,ventricular dysfunction
3008,assignment
3009,diameters
3010,extubated
3011,cardiac murmurs
3012,aortic insufficiency
3013,reduced
3014,lb
3015,men
3016,users
3017,multivariable logistic analysis
3018,bradycardic
3019,multiorgan failure
3020,epidemiology
3021,left
3022,isoforms
3023,gene-targeted
3024,parameters
3025,erythropoiesis-stimulating agents
3026,n=1543
3027,vasopeptidase inhibitors
3028,secondary
3029,etiology
3030,pathophysiology
3031,prone
3032,telephone
3033,peak vo2
3034,t1 time
3035,misdiagnosis
3036,posterior wall infarction
3037,rapid onset
3038,hfpef
3039,idiopathic dilated cardiomyopathy
3040,unreliable
3041,cited
3042,preserve
3043,pulse sequence
3044,algorithms
3045,bpm
3046,healthcare
3047,age-
3048,relevance
3049,advisors
3050,cardiac arrest
3051,iron
3052,devices
3053,evident
3054,pressure
3055,at-risk
3056,tactics
3057,evidenced
3058,outline
3059,catheter ablation
3060,complexities
3061,levels
3062,high-sensitivity
3063,activation
3064,cardioverter-defibrillator device
3065,rheumatic
3066,t1 / 2
3067,analysis
3068,anti-neoplastic agent
3069,myocardial collagen
3070,extracorporeal membrane oxygenation membrane support
3071,reasons
3072,congenital
3073,channels
3074,referred
3075,alendronate-
3076,pre-specified
3077,ischemia
3078,uncontrolled
3079,multihospital study
3080,intravenous
3081,1a
3082,c=24.3
3083,severe hyponatremia
3084,receptor blocker
3085,cutoff point
3086,murine myocardium
3087,mr
3088,methods
3089,heart failure with reduced
3090,meta-analyses
3091,disciplines
3092,nondiabetes
3093,glucose transporter 4
3094,mrna splicing
3095,enos-ser
3096,preserved left ventricular ejection fractions
3097,hypophosphorylation
3098,tac-induced proteomic alterations
3099,diminishing
3100,right grip
3101,residents
3102,hypothesized
3103,intubations
3104,terminal
3105,signal
3106,degenerative mitral valve
3107,ven
3108,furosemide
3109,life support
3110,sex-adjusted risk
3111,sodium
3112,standardized
3113,lean body mass ratio
3114,peak oxygen uptake
3115,hhf
3116,acute
3117,activators
3118,referral
3119,secretion
3120,magnetically levitated centrifugal-flow chronic lvas
3121,dna fragmentation
3122,prescribe
3123,medical treatment
3124,consultation
3125,conclusions
3126,overexpression
3127,structured exercise
3128,confidence interval
3129,studies
3130,indicative
3131,expenditures
3132,objective
3133,circumferential shortening
3134,infrastructure
3135,normalization
3136,surviving
3137,converts
3138,antiplatelet agents
3139,applications
3140,instituting
3141,hypertension
3142,improved
3143,preserved systolic function
3144,peripheral
3145,functional mitral stenosis
3146,indicator
3147,reliability
3148,valsartan
3149,muscular
3150,woman
3151,hazard
3152,finding
3153,beta-adrenergic receptor
3154,ras-blocker
3155,cardiac tissues
3156,thereby
3157,imaging
3158,nesiritide strategy
3159,β-blocker
3160,transduction pathways
3161,span
3162,institutional
3163,randomization
3164,basis
3165,dynamics
3166,discharges
3167,hepatic function
3168,titin hypophosphorylation
3169,skinfold
3170,relative value
3171,loss
3172,spectral analysis
3173,humanized
3174,defense mechanism
3175,emergency
3176,secondary study end point
3177,invasive hemodynamic assessments
3178,narrow qrs complex
3179,systolic pressure
3180,measured
3181,histologically
3182,acr
3183,replicate
3184,pad
3185,desensitization
3186,secondary end point
3187,acute β-adrenoceptor blockade
3188,stenosis
3189,scale
3190,pneumonia
3191,recognized
3192,metric
3193,echo-doppler studies
3194,predict
3195,signalling proteins
3196,nt-probnp
3197,staff
3198,chemotherapy
3199,context
3200,abnormal
3201,2:1 ratio
3202,25th-75th percentiles
3203,acute β-ar
3204,diuretic
3205,biventricular support
3206,bioinformatic analysis
3207,uptitration
3208,shuttle walk test
3209,overlapped
3210,tta
3211,beagle
3212,multivariate logistic regression analysis
3213,induced recovery
3214,co-primary outcome
3215,haemodynamic stress
3216,domains
3217,substantial
3218,reducing
3219,antiplatelet drugs
3220,adjunctive
3221,patient
3222,walk distance
3223,circulation
3224,se
3225,tachycardia
3226,mitochondrial oxidation
3227,exercise tolerance
3228,tests
3229,protein kinase a
3230,coronary occlusion
3231,msec
3232,transition
3233,triggers
3234,practice
3235,concomitant
3236,monitoring
3237,utilization
3238,coronary revascularization
3239,arterial elastance
3240,volumes of exercise
3241,activating
3242,interact
3243,right ventricular function
3244,community
3245,pre
3246,receptor agonist
3247,biventricular pacing
3248,mechanical circulatory support
3249,bets
3250,circumflex artery
3251,severe left ventricular dilatation
3252,myocardium
3253,professionals
3254,chronic inflammatory state
3255,chronic pulmonary arterial hypertension
3256,connection
3257,hypertrophic response
3258,epithelial
3259,further study
3260,ea
3261,nested
3262,importance
3263,sex-specific models
3264,prescribed
3265,adverse impact
3266,contextual factors
3267,mechanisms
3268,bleeding
3269,grain
3270,hf-induced remodeling
3271,tachycardia-induced heart failure
3272,across-the-board improvements
3273,telemonitoring
3274,global attenuation
3275,nanomolar
3276,jugular venous pressure
3277,anterior leaflet opening
3278,chromatin hyperacetylation
3279,groups
3280,intravenous iron
3281,all-cause hospitalization
3282,coronary artery bypass grafting
3283,intracellular
3284,cardiac pathology
3285,prostate
3286,rhythm-control
3287,anemic
3288,genomic
3289,measurable
3290,resting hr
3291,rm
3292,tension
3293,sequential phosphorylation
3294,atp
3295,soluble guanylate cyclase
3296,regression line
3297,spontaneous ventricular tachycardia
3298,tricuspid annular plane systolic excursion
3299,carotid bodies
3300,novel treatment strategies
3301,encoding
3302,low-frequency
3303,functional ms
3304,utility
3305,specificity
3306,moderate
3307,chemical
3308,hscrp
3309,sex-matched
3310,vary
3311,chordal ruptures
3312,halts
3313,thirty-seven hospitals
3314,active
3315,histological
3316,cc
3317,hypertensive
3318,afterload
3319,mechanistically
3320,natriuretic peptide
3321,implantable defibrillators
3322,consequence
3323,peptide
3324,remodelling
3325,elevated left atrial pressure
3326,band
3327,bisphosphonates
3328,peak oxygen consumption
3329,implementation
3330,reversal
3331,specific
3332,collagen deposition
3333,multivariate-adjusted odds ratio
3334,β1ars
3335,percentage
3336,receptors
3337,end-diastolic dimension
3338,heart failure treatment
3339,codes
3340,right ventricular assist devices
3341,mammalian
3342,atypical
3343,signaling pathways
3344,chronic obstructive pulmonary disease
3345,implantable cardiac defibrillator
3346,epicatechin
3347,co-morbidity
3348,tac
3349,role
3350,acetyl-lysine reader proteins
3351,rr intervals
3352,coronary perfusion
3353,financial
3354,patch closure
3355,cardiovascular event-free rate
3356,cellular dysfunction
3357,holosystolic murmur
3358,left ventricular base
3359,update
3360,p70s6k-ser
3361,histone
3362,wasting
3363,renin-angiotensin-aldosterone
3364,electrical stimulation
3365,tobacco
3366,resulted
3367,multivariate model
3368,agents
3369,embedded
3370,diet scores
3371,modulate
3372,cpcs
3373,adenosine monophosphate
3374,protection
3375,tricuspid valve
3376,observed
3377,prolapse
3378,pharmaceutically
3379,lipid-lowering
3380,cox proportional hazards models
3381,samples
3382,rv function
3383,summary
3384,rats
3385,climate
3386,eligibility
3387,continuity
3388,log-rank testing
3389,depressed
3390,bottleneck stent model
3391,bromodomain inhibition
3392,trigger
3393,simulation models
3394,fractal scaling exponent
3395,independent
3396,tidal respiration
3397,warrant
3398,myocardial
3399,decongestion
3400,regulates
3401,branches
3402,vital
3403,aim
3404,quantification
3405,synchrony
3406,persistent af
3407,littermate
3408,metabolic enzymes
3409,heart transplantations
3410,hypokalemia
3411,covariate adjustment
3412,sustainability
3413,embase
3414,regression models
3415,spectral
3416,point
3417,reflective
3418,nesiritide
3419,neurohormonal stimulation
3420,risk of incident
3421,non-ischemic heart failure samples
3422,metabolic
3423,economic impact
3424,longitudinal analysis
3425,hospitals
3426,icds
3427,pharmacological
3428,intrinsic left ventricular dysfunction
3429,morphology
3430,rate ratio
3431,predictive model
3432,cardiac chromatin
3433,reduced ejection fraction
3434,lean mass index
3435,spontaneous vt
3436,hospitalizations
3437,electrocardiographers
3438,anaerobic metabolism
3439,domain
3440,index
3441,consenting
3442,treat
3443,nominal
3444,multiple myeloma
3445,embryonic kidney
3446,atherosclerotic cad
3447,zsf1
3448,nonadherence
3449,ie
3450,antitumor activity
3451,pathway analysis
3452,inflammatory markers
3453,race
3454,cardiac vagal tone
3455,s'septal
3456,grip
3457,injected
3458,implantable cardiac arrhythmia devices
3459,end systolic volume index
3460,case-fatality rate
3461,protein-c phosphorylation
3462,viscoelastic
3463,heart rate variability
3464,assays
3465,truncated
3466,electromechanics
3467,production
3468,dystrophin-associated protein complex
3469,axis
3470,molecular mechanism
3471,weight loss
3472,psychometric
3473,rest
3474,late-onset
3475,elevations
3476,uncertain
3477,improvements
3478,malondialdehyde
3479,recapitulates
3480,presence
3481,vehicle
3482,confirmation
3483,female
3484,link
3485,paradigm
3486,heart disease
3487,organic
3488,hh
3489,testimonies
3490,extracted
3491,developments
3492,cardioverter-defibrillators
3493,step forward
3494,guideline-mandated
3495,hyperlipidaemia
3496,skeletal muscle mass
3497,right ventricle overload
3498,surviving left ventricle
3499,defibrillator
3500,protein content
3501,methotrexate
3502,reverse remodeling
3503,psychosocial
3504,heart magnetic resonance imaging
3505,flow-mediated dilatation diameter
3506,base
3507,catheter system
3508,mitral
3509,severe systolic dysfunction
3510,blood transfusions
3511,p38alpha
3512,vasopressin
3513,stay
3514,observational studies
3515,inroads
3516,drug
3517,secondary outcomes
3518,sampling frame
3519,aerobic capacity
3520,implanted monitoring devices
3521,age-by-lvef
3522,heart beat
3523,acute heart failure
3524,electromechanical delay
3525,intubation
3526,6-minute walk distance
3527,adjuvant
3528,care transfer policy
3529,population-based study
3530,differences
3531,aerobic
3532,transcatheter aortic valve procedure
3533,norepinephrine-induced
3534,stent coated
3535,ingenuity pathway analysis
3536,peak
3537,angiotensin
3538,multivariable cox modeling
3539,mitochondrial proteome
3540,rate control
3541,abrogated
3542,non-dnx
3543,whites
3544,data extraction
3545,et
3546,self-care
3547,p=0·035
3548,body
3549,relationships
3550,idiopathic-dilated cardiomyopathy
3551,meta-analysis
3552,antihyperglycemic agents
3553,cogeneration
3554,motion
3555,brief review
3556,p=0.014
3557,implanted left-to-right
3558,explants
3559,released
3560,visits
3561,cardiopulmonary exercise
3562,centers
3563,cardiac magnetic resonance
3564,functioning
3565,upregulated
3566,type ii regulatory
3567,non-survivors
3568,fluorescence resonance energy transfer-based
3569,real-world setting
3570,lbbb
3571,requiring
3572,genotype
3573,blunted
3574,fontan
3575,ventricular
3576,reduced lv ejection fraction
3577,atrial pacing
3578,vasopressin receptor antagonist
3579,functional enrichment analysis
3580,reproducible
3581,(tac)-induced heart failure
3582,severely reduced lvef
3583,performed
3584,icd-hf
3585,regimens
3586,auscultation
3587,dogs
3588,hf index
3589,effectors
3590,refractory cardiogenic shock
3591,challenges
3592,anecdotal
3593,reductions
3594,non-invasively
3595,cardiomyocyte bioenergetics
3596,insulin-resistance
3597,selective β-blocker
3598,black race
3599,expertise
3600,non-aas
3601,overweight body mass index
3602,methodology
3603,valvular disease
3604,autonomic balance
3605,burden
3606,endoplasmic reticulum
3607,influx
3608,vehicle-treated
3609,xo inhibition
3610,right ventricular contractile reserve
3611,anthracyclines
3612,expected
3613,cardiomyocytes
3614,score
3615,pre-hct chest radiation
3616,hemodynamically
3617,exposed
3618,cell adhesion genes
3619,infarcted
3620,pyridostigmine
3621,pacing-induced chf
3622,hfvt(-)
3623,annular
3624,sternal sparing approach
3625,permeability
3626,multivariable models
3627,likely
3628,determinants
3629,acute decompensated hf
3630,6-mwt
3631,strengths
3632,chronic decompensated heart failure
3633,curves
3634,clinical practice guideline
3635,palliation
3636,proportional hazards analyses
3637,translating
3638,certified
3639,cardiac volume overload
3640,inflammation-stimulated resistin
3641,environment
3642,cardiovascular disease
3643,nonsignificant
3644,relevant
3645,baroreflex activation therapy
3646,reviewers
3647,predictive cutoff value
3648,extracellular flux analyzer
3649,concept
3650,velocity time
3651,cardiac looping
3652,offset
3653,hypothesis-generating findings
3654,pressure-overload
3655,life expectancy
3656,cardiomyopathic restriction
3657,primary oscillations
3658,systems
3659,bottleneck stent
3660,adjusted hazard ratio
3661,borderline
3662,ras blockers
3663,outperformed left ventricular ejection fraction
3664,ischemic mr
3665,tachy
3666,hypertensive lv dysfunction
3667,non-diastolic
3668,pulse
3669,breast cancer
3670,coronary artery bypass
3671,renin
3672,cardiac function
3673,potential predictors
